Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4364663

O=C(Nc1ccc2cc1CCc1cccc(c1)Nc1ncc(Cl)c(n1)N2)N[C@@H]1CCN(C(=O)c2ccccc2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 9/20 0.47
CDK14 O94921 2/20 0.36
CCNY Q8ND76 2/20 0.36
RIPK1 Q13546 1/20 0.36
JAK2 O60674 7/20 0.35
JAK1 P23458 7/20 0.35
JAK3 P52333 7/20 0.35
TYK2 P29597 6/20 0.35
STK4 Q13043 1/20 0.35
STK3 Q13188 1/20 0.35
STK26 Q9P289 1/20 0.35
STK24 Q9Y6E0 1/20 0.35
IDH1 O75874 1/20 0.34
IDH2 P48735 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK7 P50613 1/20 0.34
CCNH P51946 1/20 0.34
MNAT1 P51948 1/20 0.34
EPHX1 P07099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4358255 1.00 ALK (0.47) ALKCDK14CCNYRIPK1JAK2
Trifluoroacetic Acid SCHEMBL4356785 0.96 ALK (0.46) ALKCDK14CCNYJAK2JAK1
SCHEMBL1074561 0.96 ALK (0.50) ALKJAK2JAK1JAK3TYK2
SCHEMBL1075511 0.96 ALK (0.50) ALKJAK2JAK1JAK3TYK2
Trifluoroacetic Acid SCHEMBL4362869 0.94 ALK (0.44) ALKCDK14CCNYJAK2JAK1
Trifluoroacetic Acid SCHEMBL4358015 0.94 ALK (0.40) ALKCDK14CCNYRIPK1JAK2
Trifluoroacetic Acid SCHEMBL4362708 0.93 ALK (0.45) ALKCDK14CCNY
Trifluoroacetic Acid SCHEMBL4360830 0.93 ALK (0.50) ALKJAK2JAK1JAK3TYK2
Trifluoroacetic Acid SCHEMBL4361604 0.93 ALK (0.50) ALKJAK2JAK1JAK3TYK2
Trifluoroacetic Acid SCHEMBL4361890 0.92 ALK (0.45) ALKJAK2JAK1JAK3TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885CDK14 374/4885CCNY 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.